Intellinetics, Inc. specializes in document management and workflow solutions, primarily serving the healthcare and government sectors in the United States. The company's competitive edge lies in its proprietary software platform, which offers advanced features such as cloud storage and data analytics, enabling clients to streamline operations and improve compliance.
Intellinetics generates revenue primarily through software licensing and subscription fees, supplemented by professional services and maintenance contracts. The company's strong gross margin of 66% indicates pricing power, driven by its unique software capabilities and established client relationships.
Adoption rates of cloud-based document management solutions in healthcare
Regulatory changes impacting data management requirements
Partnerships with major healthcare providers
Customer retention rates and upsell opportunities
Technological disruption from emerging competitors offering advanced AI-driven solutions
Regulatory changes that could impose additional compliance burdens on clients
Increased competition from larger software firms entering the document management space
Potential loss of key clients to competitors with more comprehensive offerings
Low liquidity as indicated by a current ratio of 0.90, which may limit operational flexibility
Negative net margins indicating ongoing financial strain
moderate - The demand for software solutions can be sensitive to economic cycles, particularly in sectors like healthcare that are influenced by government spending and consumer confidence.
Interest rates affect Intellinetics primarily through the cost of financing for growth initiatives. Higher rates could dampen investment in technology upgrades by clients, impacting demand for its solutions.
minimal - Intellinetics has low debt levels, which reduces its exposure to credit market fluctuations.
growth - Investors looking for technology companies with potential for scalability and recurring revenue streams.
high - The stock has shown significant volatility with a 1-year return of -55%, indicating high risk.